LGVN
Longeveron Inc.
NASDAQ · Healthcare · Biotechnology · US
$6.81
+3.50%Margins
Gross margin
69.8%
EBITDA margin
-1927.2%
EBIT margin
-1992.8%
Net margin
-1977.6%
FCF margin
-1740.4%
-225.7%
Return on equity
-151.6%
Return on assets
-215.4%
Return on invested capital
0.06x
Asset turnover
-$20.4M
Cash from operations
$3.16
Cash per share
Margins, returns on capital and operating efficiency from the latest trailing period · Data as of Jun 1, 2026